The first meta-analysis, which included three randomized clinical trials (Checkmate-057 (N = 582), POPLAR (N = 287), and OAK (N = 850)), highlighted how ICIs significantly improved the overall survival in previously treated KRAS mutant NSCLC patients (HR, 0.64; p = 0.03) [52]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.